A Phase 3, Open-label, Multicenter Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients With Elevated Resting Heart Rate
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2018
Price : $35 *
At a glance
- Drugs Ivabradine (Primary)
- Indications Tachycardia
- Focus Therapeutic Use
- Sponsors Amgen
- 15 Nov 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Sep 2018 Planned End Date changed from 6 Sep 2019 to 19 Feb 2020.
- 25 Sep 2018 Planned primary completion date changed from 6 Sep 2019 to 19 Feb 2020.